J. Rademaker-Lakhai

发表

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2007, Cancer Chemotherapy and Pharmacology.

A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

J. Schellens, J. Beijnen, D. Pluim, 2004, Clinical Cancer Research.

Relationship between cisplatin administration and the development of ototoxicity.

J. Schellens, J. Beijnen, P. Baas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

J. Schellens, J. Beijnen, P. Baas, 2005, Anti-cancer drugs.

Phase I and pharmacologic study of enzastaurin HCl, gemcitabine and cisplatin.

J. Schellens, J. Beijnen, E. Voest, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

V. Tjan-Heijnen, F. Erdkamp, M. Bos, 2018, Breast Cancer Research and Treatment.

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

T. D. de Reijke, J. Schellens, J. Beijnen, 2005, Clinical Cancer Research.

Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational New Drugs.

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

J. Schellens, H. Rosing, J. Beijnen, 2005, Investigational new drugs.

Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients

J. Schellens, J. Beijnen, M. Campone, 2007, Cancer Chemotherapy and Pharmacology.

A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

J. Schellens, J. Beijnen, S. Howell, 2004, Clinical Cancer Research.

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

V. Tjan-Heijnen, F. Erdkamp, M. Bos, 2020, Acta oncologica.

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer

J. Schellens, J. Beijnen, E. Voest, 2007, Clinical Cancer Research.

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

R. Timman, V. Tjan-Heijnen, F. Erdkamp, 2019, Breast Cancer Research and Treatment.

Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer.

J. Schellens, J. Beijnen, W. Meinhardt, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer.

J. Schellens, J. Beijnen, E. Voest, 2006, Journal of Clinical Oncology.